Momba Healthcare Solutions
Specialty Pharmacy Cost Reduction for Health Plans
For years, The Momba Group has partnered with health plans and healthcare organizations to solve complex staffing and workforce challenges. That work has given us a deep understanding of how healthcare organizations operate and where cost, quality, and access collide.
Our Specialty Pharmacy Strategy practice brings The Momba Group’s practical, execution-oriented approach into pharmacy cost management. We help health plans regain control of speciality drug spend without disrupting members, providers, or compliance.
Reduce Specialty Drug Spend Without Disrupting Care
Reduce Specialty Drug Spend Without Disrupting Care
The Momba Approach
We bring the same mindset that has guided our staffing and healthcare work for years: understand the environment, align stakeholders, and focus on solutions that work in the real world.
Our specialty pharmacy engagements are independent of Pharmacy Benefit Manager incentives and designed to move quickly from insight to action, with measurable results and minimal disruption.
While results vary by organization and baseline, clients commonly see:
Faster biosimilar adoption and better insight into total cost of care
Improved transparency into 340B and biosimilar economics
8–20% reductions in targeted specialty spend within the first year
Specialty Pharmacy Cost Reduction for Health Plans
340B Strategy To Improve Transparency And Capture Value
The 340B program can create meaningful value, but many plans struggle to see where that value is being captured, missed, or lost across networks, employer groups, and health systems.
We help plans make sense of the complexity and put clear, compliant structures in place.
What this means for you
- Better visibility into how 340B value flows through your network
- Reduced leakage and audit risk
- Stronger alignment with health systems and hospital partners
- Greater confidence in governance and compliance
Biosimilar Strategies That Deliver Faster Savings
Biosimilars offer one of the most immediate opportunities to reduce specialty drug costs. Still, adoption can be slow due to PBM incentives, benefit design challenges, and provider uncertainty.
We help plans create biosimilar strategies that are easier to implement and easier to support.
What this means for you
- Faster adoption of biosimilars for high-impact drugs like Humira and Stelara
- Lower net specialty drug costs with improved transparency
- Less reliance on PBM-driven rebate economics
- Maintained access, adherence, and provider trust
From Strategy to Measurable Savings
Health plans work with The Momba Group when they want progress, not just recommendations. Common engagements include:
What this means for you
- Faster adoption of biosimilars for high-impact drugs like Humira and Stelara
- Lower net specialty drug costs with improved transparency
- Less reliance on PBM-driven rebate economics
- Maintained access, adherence, and provider trust
- Direct-to-manufacturer biosimilar programs. Measuring PMPM savings, member impact, and adherence while reducing PBM dependency.
- Rebuilding 340B processes with leading health systems. Reducing leakage and improving transparency for employer groups and ASO clients with compliant documentation.
- Optimizing benefit design for Stelara-targeted biosimilars. Coordinating benefit design, utilization management, and provider education while monitoring quality metrics.
All our projects are designed to move quickly from opportunity to execution. We stay involved through pilots and early execution to ensure strategies translate into real-world results.
SUBMIT
Let’s Start the Conversation
If specialty drug costs are rising faster than your ability to manage them, there is a clearer, more sustainable path forward.
Purpose-driven healthcare solutions that create impact with every placement and every partnership.